Enovis Corporation (ENOV) P/E Ratio History
Deep ValueTrading at -3.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2009–2022
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Enovis Corporation (ENOV) trades at a price-to-earnings ratio of -3.0x, with a stock price of $27.16 and trailing twelve-month earnings per share of $-9.02.
The current P/E is 108% below its 5-year average of 40.0x. Over the past five years, ENOV's P/E has ranged from a low of 10.3x to a high of 214.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, ENOV trades at a 112% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, ENOV trades at a notable discount to the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ENOV DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ENOV Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ENOV P/E vs Peers
Orthopedics & Spine peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 7.1Lowest | 0.69 | +817%Best | |
| $2B | 29.5 | 1.52 | +31% | |
| $3B | 196.0 | - | +75% | |
| $20B | 26.3 | - | -20% | |
| $13B | 21.6 | 3.03 | +53% | |
| $10B | 17.3 | 0.56Best | +423% | |
| $5B | 32.9 | - | +5% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ENOV Historical P/E Data (2009–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q4 | Dec 31 2022 | $53.52 | $0.25 | 214.1x | +571% |
| FY2022 Q3 | Sep 30 2022 | $46.07 | $1.23 | 37.5x | +17% |
| FY2022 Q2 | Jul 01 2022 | $56.00 | $2.95 | 19.0x | -41% |
| FY2022 Q1 | Apr 01 2022 | $69.86 | $1.30 | 53.7x | +68% |
| FY2021 Q4 | Dec 31 2021 | $79.12 | $1.42 | 55.7x | +75% |
| FY2021 Q3 | Oct 01 2021 | $81.05 | $2.17 | 37.4x | +17% |
| FY2021 Q2 | Jul 02 2021 | $80.86 | $1.98 | 40.8x | +28% |
| FY2021 Q1 | Apr 02 2021 | $76.35 | $1.23 | 62.1x | +94% |
| FY2020 Q4 | - | $65.82 | $0.92 | 71.5x | +124% |
| FY2019 Q1 | Mar 29 2019 | $51.08 | $1.71 | 29.9x | -6% |
| FY2018 Q4 | Dec 31 2018 | $35.97 | $3.48 | 10.3x | -68% |
| FY2018 Q3 | Sep 28 2018 | $62.07 | $2.61 | 23.8x | -25% |
| FY2018 Q2 | Jun 29 2018 | $52.75 | $2.94 | 17.9x | -44% |
| FY2018 Q1 | Mar 30 2018 | $54.91 | $3.30 | 16.6x | -48% |
| FY2017 Q4 | Dec 31 2017 | $68.19 | $3.63 | 18.8x | -41% |
| FY2017 Q3 | Sep 29 2017 | $71.67 | $4.26 | 16.8x | -47% |
| FY2017 Q2 | Jun 30 2017 | $67.76 | $3.84 | 17.6x | -45% |
| FY2017 Q1 | Mar 31 2017 | $67.57 | $3.51 | 19.3x | -40% |
| FY2016 Q4 | Dec 31 2016 | $61.84 | $3.12 | 19.8x | -38% |
| FY2016 Q3 | Sep 30 2016 | $54.10 | $3.27 | 16.5x | -48% |
| FY2016 Q2 | Jul 01 2016 | $45.71 | $3.03 | 15.1x | -53% |
| FY2016 Q1 | Apr 01 2016 | $50.69 | $3.33 | 15.2x | -52% |
| FY2015 Q4 | - | $40.19 | $4.05 | 9.9x | -69% |
| FY2015 Q3 | Sep 25 2015 | $52.38 | $4.89 | 10.7x | -66% |
| FY2015 Q2 | Jun 26 2015 | $80.09 | $6.21 | 12.9x | -60% |
| FY2015 Q1 | Mar 27 2015 | $82.07 | $9.54 | 8.6x | -73% |
| FY2014 Q4 | Dec 31 2014 | $88.76 | $9.51 | 9.3x | -71% |
| FY2014 Q3 | Sep 26 2014 | $102.31 | $8.52 | 12.0x | -62% |
| FY2014 Q2 | Jun 27 2014 | $127.95 | $8.19 | 15.6x | -51% |
| FY2014 Q1 | Mar 28 2014 | $118.00 | $5.16 | 22.9x | -28% |
| FY2013 Q4 | - | $109.62 | $4.56 | 24.0x | -25% |
| FY2013 Q3 | Sep 27 2013 | $96.83 | $4.15 | 23.3x | -27% |
| FY2013 Q2 | Jun 28 2013 | $89.69 | $2.98 | 30.1x | -6% |
| FY2013 Q1 | Mar 29 2013 | $80.10 | $1.78 | 45.0x | +41% |
| FY2011 Q4 | Dec 31 2011 | $49.02 | $0.29 | 169.0x | +430% |
| FY2011 Q3 | Sep 30 2011 | $34.87 | $1.97 | 17.7x | -45% |
| FY2011 Q2 | Jul 01 2011 | $43.51 | $2.12 | 20.5x | -36% |
| FY2011 Q1 | Apr 01 2011 | $40.38 | $1.58 | 25.6x | -20% |
| FY2010 Q4 | Dec 31 2010 | $31.69 | $1.08 | 29.4x | -8% |
| FY2010 Q3 | Oct 01 2010 | $25.85 | $0.85 | 30.5x | -4% |
| FY2010 Q2 | Jul 02 2010 | $17.66 | $0.59 | 30.1x | -6% |
| FY2010 Q1 | Apr 02 2010 | $19.93 | $0.74 | 27.0x | -15% |
| FY2009 Q4 | - | $20.72 | $1.27 | 16.3x | -49% |
| FY2009 Q3 | Oct 02 2009 | $17.75 | $1.63 | 10.9x | -66% |
| FY2009 Q2 | Jul 03 2009 | $13.01 | $2.43 | 5.4x | -83% |
Average P/E for displayed period: 31.9x
ENOV Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
17+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ENOV — Frequently Asked Questions
Quick answers to the most common questions about buying ENOV stock.
What is ENOV's P/E ratio?
Enovis Corporation (ENOV) trailing twelve-month P/E ratio is -3.0x, based on TTM diluted EPS of $-9.02. The 5-year average P/E is 40.0x and the historical range spans 10.3x to 214.1x.
Is ENOV stock overvalued or undervalued?
ENOV trades at -3.0x P/E, below its 5-year average of 40.0x. At the 0th percentile of its historical range (10.3x–214.1x), the stock is priced at a discount to its own history.
Is ENOV stock expensive?
No, ENOV is not expensive on a historical basis. The current P/E of -3.0x is below the 5-year average of 40.0x and sits at the 0th percentile of its valuation range.
What is ENOV's historical P/E range?
Over the past 5 years, ENOV's P/E ratio has ranged from 10.3x to 214.1x, with a median of 23.8x and an average of 40.0x. The current P/E of -3.0x places the stock at the 0th percentile of this range. Full historical data spans 2009–2022.
How does ENOV's P/E compare to the S&P 500?
ENOV trades at -3.0x P/E versus the S&P 500 median of 21.8x. The 114% discount to the market suggests lower growth expectations or perceived higher risk.
How does ENOV's valuation compare to Healthcare peers?
Enovis Corporation P/E of -3.0x compares to the Healthcare sector median of 24.6x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ENOV's PEG ratio?
ENOV PEG ratio is N/A, based on a P/E of -3.0x and EPS growth of -39.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ENOV's earnings yield?
ENOV earnings yield is N/A, the inverse of its -3.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.